Dianthus Therapeutics Inc (DNTH)

$18.36 -0.39 (-2.08%)
Market Cap 603.00M
Revenue (ttm) 6.24M
Net Income (ttm) -84.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,361.70%
Debt to Equity Ratio 0.00
Volume 210,200
Avg Vol 371,326
Day's Range N/A - N/A
Shares Out 32.16M
Stochastic %K 1%
Beta 1.48
Analysts Strong Sell
Price Target $51.40

Latest News on DNTH

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

May 22, 2025, 4:10 PM EDT - 16 hours ago

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

May 12, 2025, 4:01 PM EDT - 10 days ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

May 5, 2025, 7:00 AM EDT - 18 days ago

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

Apr 29, 2025, 7:00 AM EDT - 24 days ago

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Mar 11, 2025, 4:01 PM EDT - 2 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

Mar 5, 2025, 7:00 AM EST - 2 months ago

Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

Feb 26, 2025, 7:00 AM EST - 3 months ago

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

Jan 30, 2025, 7:00 AM EST - 4 months ago

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:00 AM EST - 4 months ago

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Nov 7, 2024, 4:01 PM EST - 7 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Nov 4, 2024, 7:00 AM EST - 7 months ago

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

Oct 15, 2024, 7:00 AM EDT - 7 months ago

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Aug 8, 2024, 4:01 PM EDT - 10 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition

Jul 29, 2024, 3:45 PM EDT - 10 months ago

Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

Jun 28, 2024, 11:30 AM EDT - 11 months ago

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 4:30 PM EDT - 1 year ago

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

May 8, 2024, 4:30 PM EDT - 1 year ago

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 3, 2024, 4:30 PM EDT - 1 year ago

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 7, 2024, 4:30 PM EST - 1 year ago

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

Feb 26, 2024, 7:00 AM EST - 1 year ago

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

Sep 11, 2023, 11:33 AM EDT - 1 year ago

Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA

Aug 7, 2023, 4:03 PM EDT - 1 year ago

MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

May 3, 2023, 7:00 AM EDT - 2 years ago

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

Mar 31, 2023, 4:10 PM EDT - 2 years ago

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

Magenta Therapeutics to Explore Strategic Alternatives

Feb 2, 2023, 4:05 PM EST - 2 years ago

Magenta Therapeutics to Explore Strategic Alternatives

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety

Jan 25, 2023, 4:05 PM EST - 2 years ago

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety

Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial

Dec 20, 2022, 9:00 AM EST - 2 years ago

Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial

Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

Dec 12, 2022, 4:30 PM EST - 2 years ago

Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

Dec 12, 2022, 8:00 AM EST - 2 years ago

Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights

Nov 3, 2022, 9:01 AM EDT - 2 years ago

Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights

Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2022, 9:01 AM EDT - 2 years ago

Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting

Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

Nov 1, 2022, 8:00 AM EDT - 2 years ago

Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

Aug 17, 2022, 8:00 AM EDT - 3 years ago

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference

Aug 2, 2022, 8:00 AM EDT - 3 years ago

Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights

May 16, 2022, 8:00 AM EDT - 3 years ago

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights

Magenta Therapeutics Trims R&D, Cuts Workforce

Apr 14, 2022, 12:23 PM EDT - 3 years ago

Magenta Therapeutics Trims R&D, Cuts Workforce

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

Apr 14, 2022, 8:00 AM EDT - 3 years ago

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights

Mar 8, 2022, 8:00 AM EST - 3 years ago

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights

Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference

Mar 3, 2022, 8:00 AM EST - 3 years ago

Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

Jan 10, 2022, 8:00 AM EST - 3 years ago

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B.

Jan 5, 2022, 8:00 AM EST - 3 years ago

Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B.

Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting

Dec 14, 2021, 9:00 AM EST - 3 years ago

Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

Nov 4, 2021, 9:10 AM EDT - 3 years ago

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting

Nov 4, 2021, 9:09 AM EDT - 3 years ago

Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting